To view this email as a web page, click here

Today's Rundown

Featured Story

Leading longevity researcher accused of sexual harassment

Until this week, Aubrey de Grey was best known as the longevity researcher who predicted the first human to live 1,000 years may already be alive. Now, de Grey stands accused of being a sexual predator. 

read more

Top Stories

Aprea gets 2nd clinical hold in a week, this time for lymphoid malignancy study

Aprea saw its shares slide into the red today as the FDA doubled down on icing its trial work. In a brief statement, the biotech said the FDA has placed a clinical hold on a test of eprenetapopt with AstraZeneca’s Calquence, or with Roche/AbbVie’s Venclexta and Roche/Biogen’s Rituxan, in lymphoid malignancies.

read more

Merck NK cell ally Artiva splashes out on new digs in San Diego

In the challenging, capacity-constrained cell therapy sector, the multiyear move toward leaner, more virtual models of drug development is reversing. Now, biotechs want their own infrastructure—and are taking out leases to secure the ability to do work in-house.

read more

From 'party drug' to ayahuasca to 'Sally D': ATAI sets up next shop for treating mental health

Another day, another subsidiary for mental health treatments. ATAI Life Sciences unveiled Revixia, which will investigate a psychoactive plant from the mint family in potentially treating treatment-resistant depression, substance use disorder and pain.

read more

Debut Biotech makes its entrance with a $22M series A for cell-free biomanufacturing facility

Debut Biotech wants to be the next leading biomanufacturer but with a cell-free approach to commercializing ingredients for food and wellness products, cosmetics, colors, therapeutics and other areas. Investors are buying into the idea with $22.6 million to help build a facility in San Diego.

read more

Overcoming resistance to cancer immunotherapy by targeting garbage-cleaning cells in tumors

Combining immunotherapy, anti-angiogenic drugs and chemotherapy to treat non-small cell lung cancer hasn't proven to be all that effective. Now, a new study suggests that a four-drug combination including a CSF1R inhibitor can target tumor-associated macrophages and improve the anti-tumor response.

read more

Moderna's sky-high market value 'unjustifiable' to one analyst, story stock to another as it tops the likes of Merck and Amgen

Moderna's record-breaking $200 billion market value earlier this week has split Wall Street as one analyst says it's gone from "unreasonable to ridiculous."

read more

HIMSS21 Roundup—Epic rolls out customer story-sharing site; Young inventor's advice for health tech innovators

Here are a few slices of news and life from the first day of the 2021 Healthcare Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition on Monday.

read more

Resources

Whitepaper: How to build a robust packaging strategy for rapid commercialization

Learn how to build a robust packaging strategy and the key technical considerations in packaging design and operational planning to enable rapid commercialization of pharmaceuticals.

eBook: Accelerate recruitment with a decentralized clinical trial strategy

Learn how a decentralized clinical trial strategy improves patient recruitment, reduces drop-out rates, and ultimately streamlines the path to the next trial phase.

Whitepaper: Understanding the CMC regulatory landscape for cell and gene therapy products

Learn how regulations are changing and key considerations for commercializing cell and gene therapies without sacrificing quality.

Whitepaper: Navigating the Digital Transformation Journey

Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Content Hub: Post-Marketing Safety Studies

Learn about key post-marketing safety study solutions, including registries and REMS, and how they can most effectively help meet regulatory requirements and maximize patient access.

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Events